Successful solid organ transplantation reflects meticulous attention to the details of
immunosuppression, balancing risks for graft rejection against risks for infection. The “net …

Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies.
Primary antibody deficiency (PAD) is the result of intrinsic genetic defects, whereas …

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant
numbers of patients with hematological cancers. While these unique immunotherapies have …

CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …

Secondary immunodeficiency is reported in most patients with hematological malignancies
such as chronic lymphocytic leukemia and multiple myeloma. The aim of our review was to …

Objectives Secondary antibody deficiency (SAD), associated with severe, recurrent or
persistent infections, is common in patients with haematological malignancies (HM), but …

Secondary immunodeficiencies occur as a consequence of various diseases, including
hematological malignancies, and the use of pharmacological therapies, such as …

Background Rituximab is a B-cell depleting agent used in B-cell malignancies and
autoimmune diseases. A subset of adult patients may develop prolonged and symptomatic …

Common variable immunodeficiency disorders refer to a relatively common primary immune
deficiency group of diseases that present with infectious and inflammatory complications …

Over the past 3 decades, IgG has been broadly used as replacement therapy in patients of
all ages with primary antibody deficiencies. Successful use of therapeutic IgG to prevent …